Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407854 | 0.78 | KDM4E (0.46) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL3581379 | 0.75 | FFAR1 (0.42) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL3590109 | 0.74 | KDM4E (0.44) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL3583609 | 0.72 | KDM4E (0.44) | PPARGKDM4EPOLBALDH1A1HPGD | |
| SCHEMBL13637288 | 0.72 | KDM4E (0.44) | KDM4EPOLBRAB9AALDH1A1HPGD | |
| SCHEMBL3589424 | 0.70 | KDM4E (0.42) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL13442138 | 0.70 | PPARD (0.36) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL27484846 | 0.69 | HDAC1 (0.50) | PPARGKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13637284 | 0.68 | FFAR1 (0.39) | PPARGKDM4EPOLBNPC1RAB9A | |
| SCHEMBL13442153 | 0.68 | KDM4E (0.36) | PPARGKDM4EPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | claimed |
| EP-1776111-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-04-25 | — | — | EP | claimed |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2006-03-16 | — | — | US | claimed |
| WO-2006020916-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1776111-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | METABOLEX, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006020916-A2 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, PPARA | PPARG 1/4885KDM4E 3867/4885POLB 2595/4885 |
| US-20060058301-A1 | Modulators of PPAR and methods of their preparation | PPARG, PPARD, PPARA | PPARG 1/4885KDM4E 3867/4885POLB 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.